{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:09:33Z","timestamp":1789207773632,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb K.K."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We investigated the factors associated with treatment discontinuation and safety of abatacept treatment up to 5\u00a0years as the first-line biologic in Japanese patients with rheumatoid arthritis (RA) of moderate disease activity (MDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 5-year data from the Orencia\u00ae Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study (UMIN000021263). We examined the factors associated with treatment discontinuation, overall and age-stratified safety, and effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 279 analyzed patients, the cumulative incidence (95% CI) of discontinuation was 0.210 (0.158\u20130.262) for insufficient effectiveness and 0.266 (0.208\u20130.323) for adverse events (AEs). Older age (subdistribution hazard ratio [95% CI] 0.970 [0.946\u20130.995]; P\u2009=\u2009.018) and anti-citrullinated peptide antibody-positive status (0.284 [0.140\u20130.575]; P\u2009&amp;lt;\u2009.001) were associated with lower risk of discontinuation due to insufficient effectiveness. Presence of comorbidities was associated with greater risk of discontinuation due to AEs. The frequencies of AEs and adverse drug reactions remained stable or decreased over time. The safety was consistent with prior analyses of ORIGAMI and comparable among three age groups (&amp;lt;65, \u226565 to &amp;lt;75, and\u2009\u226575\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Five-year results of the ORIGAMI study provide further evidence supporting the factors associated with long-term treatment continuation and safety of subcutaneous abatacept in patients with RA of MDA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf118","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:16:04Z","timestamp":1765372564000},"page":"526-536","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with treatment discontinuation and age-stratified safety of abatacept in Japanese patients with rheumatoid arthritis: 5-year results of the ORIGAMI study"],"prefix":"10.1093","volume":"36","author":[{"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo ,","place":["Japan"]},{"name":"Department of Rheumatology, International University of Health and Welfare School of Medicine , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa Medical University Research Administration Center, Showa Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Misaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center , Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, NHO \u00a0 Asahikawa Medical Center, Hokkaido ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Oshikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Kumamoto Hospital , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University , Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Komiya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Kanagawa ,","place":["Japan"]},{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Izumi Himawari Clinic , Miyagi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Yoshitama","sequence":"additional","affiliation":[{"name":"Yoshitama Clinic for Rheumatic Diseases , Kagoshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkichi","family":"Himeno","sequence":"additional","affiliation":[{"name":"Himeno Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Medical Affairs, Ono Pharmaceutical Co., Ltd. , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Immunology Medical, Bristol Myers Squibb K.K ., Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2026091205323685200_ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40266-016-0374-1","article-title":"Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance","volume":"33","author":"Ishchenko","year":"2016","journal-title":"Drugs Aging"},{"key":"2026091205323685200_ref2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of health insurance claims and specific health checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2026091205323685200_ref3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","article-title":"Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"2026091205323685200_ref4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40266-025-01195-4","article-title":"Management of late-onset rheumatoid arthritis with treat-to-target strategy","volume":"42","author":"Harigai","year":"2025","journal-title":"Drugs Aging"},{"key":"2026091205323685200_ref5","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1001\/archinte.160.18.2717","article-title":"Preventable medical injuries in older patients","volume":"160","author":"Rothschild","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026091205323685200_ref6","doi-asserted-by":"crossref","first-page":"e0296821","DOI":"10.1371\/journal.pone.0296821","article-title":"Burden of non-serious infections during biological use for rheumatoid arthritis","volume":"19","author":"Bergmans","year":"2024","journal-title":"PLoS One"},{"key":"2026091205323685200_ref7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","author":"Ozen","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2026091205323685200_ref8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091205323685200_ref9","doi-asserted-by":"crossref","first-page":"e001235","DOI":"10.1136\/rmdopen-2020-001235","article-title":"Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis","volume":"7","author":"Riley","year":"2021","journal-title":"RMD Open"},{"key":"2026091205323685200_ref10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026091205323685200_ref11","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2026091205323685200_ref12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s40744-024-00689-8","article-title":"Incidence of malignancies and the association with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis: a time-dependent analysis from the IORRA patient registry","volume":"11","author":"Harigai","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026091205323685200_ref13","doi-asserted-by":"crossref","first-page":"1349533","DOI":"10.3389\/fmed.2024.1349533","article-title":"Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry","volume":"11","author":"Manfredi","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026091205323685200_ref14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4081\/reumatismo.2024.1608","article-title":"Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort","volume":"76","author":"Molteni","year":"2024","journal-title":"Reumatismo"},{"key":"2026091205323685200_ref15","doi-asserted-by":"crossref","first-page":"e0274775","DOI":"10.1371\/journal.pone.0274775","article-title":"Comparing the effectiveness and safety of abatacept and tocilizumab in elderly patients with rheumatoid arthritis","volume":"17","author":"Temmoku","year":"2022","journal-title":"PLoS One"},{"key":"2026091205323685200_ref16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1620\/tjem.250.153","article-title":"Better retention of abatacept is associated with high rheumatoid factor: a five-year follow-up study of patients with rheumatoid arthritis","volume":"250","author":"Okazaki","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"2026091205323685200_ref17","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1080\/14397595.2018.1525019","article-title":"Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: results from a multicenter registry system","volume":"29","author":"Takahashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref18","doi-asserted-by":"crossref","first-page":"e003160","DOI":"10.1136\/rmdopen-2023-003160","article-title":"Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"9","author":"Ebina","year":"2023","journal-title":"RMD Open"},{"key":"2026091205323685200_ref19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/mr\/roab050","article-title":"Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance","volume":"32","author":"Harigai","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/mr\/roab090","article-title":"Effectiveness and safety of subcutaneous abatacept in biologic-na\u00efve RA patients at week 52: a Japanese multicentre investigational study (ORIGAMI study)","volume":"32","author":"Tamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/mr\/roac032","article-title":"Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-na\u00efve patients with rheumatoid arthritis: post-hoc subgroup analysis of the ORIGAMI study","volume":"33","author":"Azuma","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/mr\/road082","article-title":"Contribution of the factors to EuroQol 5 dimensions in rheumatoid arthritis patients achieving low disease activity\/remission with abatacept treatment: post hoc subgroup analyses of the Japanese real-world observational \u2018ORIGAMI\u2019 study","volume":"34","author":"Harigai","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/mr\/road045","article-title":"Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-na\u00efve patients with rheumatoid arthritis: post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)","volume":"34","author":"Misaki","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/mr\/roae043","article-title":"Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-na\u00efve rheumatoid arthritis patients: interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)","volume":"35","author":"Misaki","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.11465","article-title":"Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis","volume":"49","author":"Matsuda","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026091205323685200_ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today's treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref28","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.jtauto.2019.100016","article-title":"Subcutaneous abatacept in rheumatoid arthritis: a real-life experience","volume":"2","author":"Sarmiento-Monroy","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"2026091205323685200_ref29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026091205323685200_ref30","doi-asserted-by":"crossref","first-page":"19717","DOI":"10.1038\/s41598-020-76842-4","article-title":"A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients","volume":"10","author":"Kida","year":"2020","journal-title":"Sci Rep"},{"key":"2026091205323685200_ref31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026091205323685200_ref32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40744-021-00401-0","article-title":"Baseline anti-citrullinated protein antibody status and response to abatacept or non-TNFi biologic\/targeted-synthetic DMARDs: US observational study of patients with RA","volume":"9","author":"Harrold","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026091205323685200_ref33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026091205323685200_ref34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40266-018-0542-6","article-title":"Abatacept for treatment of rheumatoid arthritis: special focus on the elderly","volume":"35","author":"Soubrier","year":"2018","journal-title":"Drugs Aging"},{"key":"2026091205323685200_ref35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40744-021-00356-2","article-title":"Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study","volume":"8","author":"Muraoka","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2026091205323685200_ref36","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/PPA.S110147","article-title":"Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan","volume":"10","author":"Mahlich","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026091205323685200_ref37","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1038\/s41598-021-90442-w","article-title":"Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry","volume":"11","author":"Prior-Espa\u00f1ol","year":"2021","journal-title":"Sci Rep"},{"key":"2026091205323685200_ref38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2026091205323685200_ref39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ajh\/hpad108","article-title":"Age and comorbidities are associated with therapeutic inertia among older adults with uncontrolled blood pressure","volume":"37","author":"Hiura","year":"2024","journal-title":"Am J Hypertens"},{"key":"2026091205323685200_ref40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4997\/jrcpe.2021.420","article-title":"Clinical inertia in rheumatology practice","volume":"51","author":"Raveendran","year":"2021","journal-title":"J R Coll Physicians Edinb"},{"key":"2026091205323685200_ref41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2020.1855365","article-title":"Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases","volume":"50","author":"D'Amico","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2026091205323685200_ref42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026091205323685200_ref43","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026091205323685200_ref44","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"10","author":"Yamakawa","year":"2021","journal-title":"J Clin Med"},{"key":"2026091205323685200_ref45","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.170344","article-title":"Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial","volume":"45","author":"Genovese","year":"2018","journal-title":"J Rheumatol"},{"key":"2026091205323685200_ref46","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026091205323685200_ref47","doi-asserted-by":"crossref","first-page":"152313","DOI":"10.1016\/j.semarthrit.2023.152313","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026091205323685200_ref48","volume-title":"Cancer Statistics in Japan 2024.","author":"Foundation for Promotion of Cancer Research"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf118\/65838881\/roaf118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/526\/65838881\/roaf118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/526\/65838881\/roaf118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:32:49Z","timestamp":1789205569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/526\/8377252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf118","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,11]]}}}